<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453334</url>
  </required_header>
  <id_info>
    <org_study_id>1VIT14039</org_study_id>
    <nct_id>NCT02453334</nct_id>
  </id_info>
  <brief_title>Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®</brief_title>
  <acronym>IRON CLAD</acronym>
  <official_title>IRON CLAD: Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose Injection) in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Regent, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Regent, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III, multicenter, randomized, double-blinded, prospective study with two parallel&#xD;
      treatment groups. Patients who present to the hematologist/oncologist and satisfy all&#xD;
      inclusion and exclusion criteria will be eligible for participation in this 18-week study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, multicenter, randomized, double-blinded, prospective study with two&#xD;
      parallel treatment groups. Patients who present to the hematologist/oncologist and satisfy&#xD;
      all inclusion and exclusion criteria will be eligible for participation in this 18-week&#xD;
      study. Subjects who meet all inclusion criteria and no exclusion criteria, will be randomized&#xD;
      into the trial (Group A or B).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2015</start_date>
  <completion_date type="Actual">January 4, 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Week 3 to Week 18</measure>
    <time_frame>Week 3 to Week 18</time_frame>
    <description>The following participants will be considered to have met the primary endpoint:&#xD;
Participants with observed Hgb decrease from baseline between 0.5 g/dL to 1.0 g/dL on two consecutive visits between Weeks 3 and 18.&#xD;
Participants with observed Hgb decrease from baseline ≥1.0 g/dL at one visit.&#xD;
Participants who have a non-study intervention prior to Week 18.&#xD;
Participants who discontinue prior to Week 18 for lack of efficacy or adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin From Baseline to Week 18 or to Nonstudy Intervention</measure>
    <time_frame>Baseline to Week 18</time_frame>
    <description>Nonstudy Intervention is defined as any of the following:&#xD;
Initiation of erythropoietin for any reason&#xD;
Blood transfusion&#xD;
IV iron&#xD;
Prescribed use of oral iron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hemoglobin Increase From Baseline ≥ 1 g/dL at Any Postbaseline Visits Without Receiving a Nonstudy Intervention</measure>
    <time_frame>Baseline to Week 18</time_frame>
    <description>Summary of number and percentage(%) of participants with Hgb increase ≥ 1 g/dL increase at any time point in the absence of non-study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Received Nonstudy Intervention</measure>
    <time_frame>Baseline to week 18</time_frame>
    <description>Intervention is defined as any of the following:&#xD;
Initiation of erythropoietin for any reason&#xD;
Blood transfusion&#xD;
IV iron&#xD;
Prescribed use of oral iron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hemoglobin &gt; 12 g/dL in the Absence of Non-study Intervention</measure>
    <time_frame>Baseline to week 18</time_frame>
    <description>Intervention is defined as any of the following:&#xD;
Initiation of erythropoietin for any reason&#xD;
Blood transfusion&#xD;
IV iron&#xD;
Prescribed use of oral iron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hemoglobin Increase ≥ 1 g/dL in the Absence of Non-study Intervention</measure>
    <time_frame>Baseline to Week 18</time_frame>
    <description>Participants who discontinued or completed the study, or received a non-study intervention before having an increased in Hgb ≥ 1 g/dL will be censored at last study visit or time of receiving non-study intervention, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring a Blood Transfusion</measure>
    <time_frame>Baseline to week 18</time_frame>
    <description>Summary of the number (percentage) of participants requiring a blood transfusion at any time during the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</measure>
    <time_frame>Baseline to Week 3</time_frame>
    <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</measure>
    <time_frame>Baseline to Week 9</time_frame>
    <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit.</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit.</measure>
    <time_frame>Baseline to Week 15</time_frame>
    <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</measure>
    <time_frame>Baseline to Week 18</time_frame>
    <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Week 18</measure>
    <time_frame>Baseline to Week 18</time_frame>
    <description>Patients who discontinued or completed the study, or received a nonstudy intervention before having an increase in Hgb ≥ 0.5 g/dL were censored at last study visit or time of receiving nonstudy intervention, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Week 18</measure>
    <time_frame>From Baseline to Week 18</time_frame>
    <description>Patients who discontinued or completed the study, or received a nonstudy intervention before having an increase in Hgb ≥ 0.5 g/dL were censored at last study visit or time of receiving nonstudy intervention, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Change in Hemoglobin With Baseline Hepcidin Level</measure>
    <time_frame>Baseline to Week 18.</time_frame>
    <description>For participants who receive non-study intervention or early withdraw from the study, the time of intervention or early withdrawal will be considered as end of study, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Score of the Functional Assessment of Chronic Illness Therapy Fatigue(FACIT-Fatigue) Scale Mean Change From Baseline to Week 18</measure>
    <time_frame>Baseline to Week 18</time_frame>
    <description>Summary of the actual value and change from baseline in total score of Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue Scale). Ranges from 0-52 and higher scores mean better Quality of Life (QOL). Data collected after receiving non-study intervention will not be included in the summary.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Cancer and Chemotherapy Related Anemia</condition>
  <arm_group>
    <arm_group_label>Injectafer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injectafer</intervention_name>
    <arm_group_label>Injectafer</arm_group_label>
    <other_name>ferric carboxymaltose injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects (male of female) ≥ 18 years of age able to give informed consent to the&#xD;
             study.&#xD;
&#xD;
          -  Subjects with non-myeloid malignancies&#xD;
&#xD;
          -  Receiving chemotherapy as part of their cancer treatment with at least 4 weeks of&#xD;
             treatment remaining.&#xD;
&#xD;
          -  Screening visit central laboratory hemoglobin (Hgb) ≤11 g/dL, but ≥8 g/dL.&#xD;
&#xD;
          -  Ferritin between 100 and 800 ng/mL and transferrin saturation (TSAT) =&lt;35%&#xD;
&#xD;
          -  Subjects must have Eastern Coopertative Oncology Group (ECOG) performance status of&#xD;
             0-2.&#xD;
&#xD;
          -  Life expectancy of at least 6 months.&#xD;
&#xD;
          -  Demonstrate the ability to understand the requirements of the study, willingness to&#xD;
             abide by study restrictions and to return for the required assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participation in a ferric carboxymaltose clinical trial.&#xD;
&#xD;
          -  Known hypersensitivity reaction to any component of ferric carboxymaltose.&#xD;
&#xD;
          -  Subjects with overt bleeding&#xD;
&#xD;
          -  Any anemia treatment within 4 weeks before inclusion (oral iron, IV iron, transfusion,&#xD;
             or erythropoiesis-stimulating agents).&#xD;
&#xD;
          -  Subjects on erythropoiesis-stimulating agents.&#xD;
&#xD;
          -  Requiring dialysis for the treatment of chronic kidney disease.&#xD;
&#xD;
          -  Any non-viral infection.&#xD;
&#xD;
          -  Known positive hepatitis with evidence of active disease.&#xD;
&#xD;
          -  Received an investigational drug within 30 days of screening.&#xD;
&#xD;
          -  Alcohol or drug abuse within the past 6 months.&#xD;
&#xD;
          -  Hemochromatosis or other iron storage disorders.&#xD;
&#xD;
          -  Any other laboratory abnormality, medical condition or psychiatric disorders which in&#xD;
             the opinion of the Investigator would put the subject's disease management at risk or&#xD;
             may result in the subject being unable to comply with study requirements.&#xD;
&#xD;
          -  Pregnant or actively trying to become pregnant (Female subjects who are of&#xD;
             childbearing age must have a negative pregnancy test at screening and be practicing an&#xD;
             acceptable method of birth control during the study).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc.</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc.</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer Institute</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR Development Solutions</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakes Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bond Bond Clinic, P.A.</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology Hematology Associates</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MId-Illinois Hematology &amp; Oncology Associates, Ltd.</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF Saint Anthony Medical Center for Cancer Care</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Research, Inc.</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michiana Hematology Oncology, PC</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashland-Bellefonte Cancer Center</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rcca Md, Llc</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antietam Oncology and Hematology Group, P.C.</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi and Oncology Associates</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Chester Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10469</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Brookdale University Hospital and Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond University Medical Center</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waverly Hematology Oncology</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinston Medical Specialists</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology/Oncology Associates, P.A.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Blood and Cancer Care, PA</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westchase Clinical Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Francis Medical Center</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <results_first_submitted>November 2, 2020</results_first_submitted>
  <results_first_submitted_qc>April 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2021</results_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02453334/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02453334/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Injectafer</title>
          <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline</title>
          <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Injectafer</title>
          <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline</title>
          <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="122"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="244"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.0" spread="10.02"/>
                    <measurement group_id="B2" value="63.1" spread="9.26"/>
                    <measurement group_id="B3" value="63.0" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="234"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African-American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian/Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian/Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.9" spread="9.5"/>
                    <measurement group_id="B2" value="165.9" spread="9.6"/>
                    <measurement group_id="B3" value="166.4" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Iron intolerance</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG grade</title>
          <description>Eastern Cooperative Oncology Group. The ECOG grading is 0=fully active&#xD;
restricted in physical activity&#xD;
Capable of all self care unable to carry out activities&#xD;
Confined more than 50% of waking hours&#xD;
Completely disabled</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer stage</title>
          <description>Stage 0 = No cancer only abnormal cells Stage 1= Small in one area Stage 2 and 3 = Cancer is larger and grown into nearby tissues. Stage 4 = Spread to other parts of body</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Week 3 to Week 18</title>
        <description>The following participants will be considered to have met the primary endpoint:&#xD;
Participants with observed Hgb decrease from baseline between 0.5 g/dL to 1.0 g/dL on two consecutive visits between Weeks 3 and 18.&#xD;
Participants with observed Hgb decrease from baseline ≥1.0 g/dL at one visit.&#xD;
Participants who have a non-study intervention prior to Week 18.&#xD;
Participants who discontinue prior to Week 18 for lack of efficacy or adverse events.</description>
        <time_frame>Week 3 to Week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Week 3 to Week 18</title>
          <description>The following participants will be considered to have met the primary endpoint:&#xD;
Participants with observed Hgb decrease from baseline between 0.5 g/dL to 1.0 g/dL on two consecutive visits between Weeks 3 and 18.&#xD;
Participants with observed Hgb decrease from baseline ≥1.0 g/dL at one visit.&#xD;
Participants who have a non-study intervention prior to Week 18.&#xD;
Participants who discontinue prior to Week 18 for lack of efficacy or adverse events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0143</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage difference</param_type>
            <param_value>-15.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.01</ci_lower_limit>
            <ci_upper_limit>-3.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin From Baseline to Week 18 or to Nonstudy Intervention</title>
        <description>Nonstudy Intervention is defined as any of the following:&#xD;
Initiation of erythropoietin for any reason&#xD;
Blood transfusion&#xD;
IV iron&#xD;
Prescribed use of oral iron</description>
        <time_frame>Baseline to Week 18</time_frame>
        <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin From Baseline to Week 18 or to Nonstudy Intervention</title>
          <description>Nonstudy Intervention is defined as any of the following:&#xD;
Initiation of erythropoietin for any reason&#xD;
Blood transfusion&#xD;
IV iron&#xD;
Prescribed use of oral iron</description>
          <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.63" spread="1.000"/>
                    <measurement group_id="O2" value="9.75" spread="1.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.901"/>
                    <measurement group_id="O2" value="0.01" spread="0.741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="1.077"/>
                    <measurement group_id="O2" value="0.06" spread="0.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="1.015"/>
                    <measurement group_id="O2" value="0.04" spread="1.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="1.264"/>
                    <measurement group_id="O2" value="0.07" spread="1.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="1.174"/>
                    <measurement group_id="O2" value="0.37" spread="1.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="1.202"/>
                    <measurement group_id="O2" value="0.74" spread="1.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="1.394"/>
                    <measurement group_id="O2" value="0.79" spread="1.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18/ET Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="1.718"/>
                    <measurement group_id="O2" value="0.87" spread="1.475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hemoglobin Increase From Baseline ≥ 1 g/dL at Any Postbaseline Visits Without Receiving a Nonstudy Intervention</title>
        <description>Summary of number and percentage(%) of participants with Hgb increase ≥ 1 g/dL increase at any time point in the absence of non-study intervention.</description>
        <time_frame>Baseline to Week 18</time_frame>
        <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hemoglobin Increase From Baseline ≥ 1 g/dL at Any Postbaseline Visits Without Receiving a Nonstudy Intervention</title>
          <description>Summary of number and percentage(%) of participants with Hgb increase ≥ 1 g/dL increase at any time point in the absence of non-study intervention.</description>
          <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0097</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>3.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage difference</param_type>
            <param_value>16.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.19</ci_lower_limit>
            <ci_upper_limit>28.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Received Nonstudy Intervention</title>
        <description>Intervention is defined as any of the following:&#xD;
Initiation of erythropoietin for any reason&#xD;
Blood transfusion&#xD;
IV iron&#xD;
Prescribed use of oral iron</description>
        <time_frame>Baseline to week 18</time_frame>
        <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Received Nonstudy Intervention</title>
          <description>Intervention is defined as any of the following:&#xD;
Initiation of erythropoietin for any reason&#xD;
Blood transfusion&#xD;
IV iron&#xD;
Prescribed use of oral iron</description>
          <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage difference</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.85</ci_lower_limit>
            <ci_upper_limit>7.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Placebo group was used as the denominator for odds ratio calculation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5758</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hemoglobin &gt; 12 g/dL in the Absence of Non-study Intervention</title>
        <description>Intervention is defined as any of the following:&#xD;
Initiation of erythropoietin for any reason&#xD;
Blood transfusion&#xD;
IV iron&#xD;
Prescribed use of oral iron</description>
        <time_frame>Baseline to week 18</time_frame>
        <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hemoglobin &gt; 12 g/dL in the Absence of Non-study Intervention</title>
          <description>Intervention is defined as any of the following:&#xD;
Initiation of erythropoietin for any reason&#xD;
Blood transfusion&#xD;
IV iron&#xD;
Prescribed use of oral iron</description>
          <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2772</p_value>
            <p_value_desc>Placebo group was used as the denominator for odds ratio calculation</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage difference</param_type>
            <param_value>5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.01</ci_lower_limit>
            <ci_upper_limit>16.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hemoglobin Increase ≥ 1 g/dL in the Absence of Non-study Intervention</title>
        <description>Participants who discontinued or completed the study, or received a non-study intervention before having an increased in Hgb ≥ 1 g/dL will be censored at last study visit or time of receiving non-study intervention, respectively</description>
        <time_frame>Baseline to Week 18</time_frame>
        <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hemoglobin Increase ≥ 1 g/dL in the Absence of Non-study Intervention</title>
          <description>Participants who discontinued or completed the study, or received a non-study intervention before having an increased in Hgb ≥ 1 g/dL will be censored at last study visit or time of receiving non-study intervention, respectively</description>
          <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
          <units>Days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Q1, 1st quartile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="15" upper_limit="20"/>
                    <measurement group_id="O2" value="23" lower_limit="21" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2, 2nd quartile or median</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="22" upper_limit="45"/>
                    <measurement group_id="O2" value="85" lower_limit="64" upper_limit="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3, 3rd quartile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106" lower_limit="69" upper_limit="NA">Not applicable because insufficient number of participants with events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="126" upper_limit="NA">Not applicable because insufficient number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Log Rank</method>
            <method_desc>P-value was estimated using logrank test stratified by country</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring a Blood Transfusion</title>
        <description>Summary of the number (percentage) of participants requiring a blood transfusion at any time during the trial.</description>
        <time_frame>Baseline to week 18</time_frame>
        <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring a Blood Transfusion</title>
          <description>Summary of the number (percentage) of participants requiring a blood transfusion at any time during the trial.</description>
          <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage difference</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.60</ci_lower_limit>
            <ci_upper_limit>9.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8924</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</title>
        <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
        <time_frame>Baseline to Day 7</time_frame>
        <population>Only participant with both a baseline and at least one post baseline value at Day 7 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</title>
          <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
          <population>Only participant with both a baseline and at least one post baseline value at Day 7 are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage difference</param_type>
            <param_value>-9.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.41</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The odds ratio (95% [CI) and P-value of treatment effect is based on Cochran-Mantel-Haenszel (CMH) chi-squared test adjusting for country. Placebo group was used as the denominator for odds ratio calculation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0740</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Placebo group was used as the denominator for odds ratio calculation.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</title>
        <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
        <time_frame>Baseline to Week 2</time_frame>
        <population>Only participant with both a baseline and at least one post baseline value at Week 2 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</title>
          <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
          <population>Only participant with both a baseline and at least one post baseline value at Week 2 are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage difference</param_type>
            <param_value>-12.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.31</ci_lower_limit>
            <ci_upper_limit>-0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0446</p_value>
            <p_value_desc>The odds ratio (95% [CI) and P-value of treatment effect is based on Cochran-Mantel-Haenszel (CMH) chi-squared test adjusting for country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Placebo group was used as the denominator for odds ratio calculation</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</title>
        <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
        <time_frame>Baseline to Week 3</time_frame>
        <population>Only participant with both a baseline and at least one post baseline value at Week 3 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</title>
          <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
          <population>Only participant with both a baseline and at least one post baseline value at Week 3 are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage difference</param_type>
            <param_value>-19.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.90</ci_lower_limit>
            <ci_upper_limit>-8.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>The odds ratio (95% [CI) and P-value of treatment effect is based on Cochran-Mantel-Haenszel (CMH) chi-squared test adjusting for country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Placebo group was used as the denominator for odds ratio calculation.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</title>
        <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>Only participant with both a baseline and at least one post baseline value at Week 6 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</title>
          <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
          <population>Only participant with both a baseline and at least one post baseline value at Week 6 are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage difference</param_type>
            <param_value>-21.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.22</ci_lower_limit>
            <ci_upper_limit>-9.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <p_value_desc>The odds ratio (95% [CI) and P-value of treatment effect is based on Cochran-Mantel-Haenszel (CMH) chi-squared test adjusting for country</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
            <estimate_desc>Placebo group was used as the denominator for odds ratio calculation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</title>
        <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
        <time_frame>Baseline to Week 9</time_frame>
        <population>Only participant with both a baseline and at least one post baseline value at Week 9 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</title>
          <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
          <population>Only participant with both a baseline and at least one post baseline value at Week 9 are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage difference</param_type>
            <param_value>-16.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.73</ci_lower_limit>
            <ci_upper_limit>-4.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0093</p_value>
            <p_value_desc>The odds ratio (95% [CI) and P-value of treatment effect is based on Cochran-Mantel-Haenszel (CMH) chi-squared test adjusting for country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
            <estimate_desc>Placebo group was used as the denominator for odds ratio calculation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit.</title>
        <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Only participant with both a baseline and at least one post baseline value at Week 12 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit.</title>
          <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
          <population>Only participant with both a baseline and at least one post baseline value at Week 12 are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage difference</param_type>
            <param_value>-4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.37</ci_lower_limit>
            <ci_upper_limit>6.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4786</p_value>
            <p_value_desc>The odds ratio (95% [CI) and P-value of treatment effect is based on Cochran-Mantel-Haenszel (CMH) chi-squared test adjusting for country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
            <estimate_desc>Placebo group was used as the denominator for odds ratio calculation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit.</title>
        <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
        <time_frame>Baseline to Week 15</time_frame>
        <population>Only participant with both a baseline and at least one post baseline value at Week 15 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit.</title>
          <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
          <population>Only participant with both a baseline and at least one post baseline value at Week 15 are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage difference</param_type>
            <param_value>-7.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.25</ci_lower_limit>
            <ci_upper_limit>4.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2084</p_value>
            <p_value_desc>The odds ratio (95% [CI) and P-value of treatment effect is based on Cochran-Mantel-Haenszel (CMH) chi-squared test adjusting for country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>Placebo group was used as the denominator for odds ratio calculation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</title>
        <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
        <time_frame>Baseline to Week 18</time_frame>
        <population>Only participant with both a baseline and at least one post baseline value at Week 18 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit</title>
          <description>Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.</description>
          <population>Only participant with both a baseline and at least one post baseline value at Week 18 are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage difference</param_type>
            <param_value>3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.33</ci_lower_limit>
            <ci_upper_limit>15.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6508</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The odds ratio (95% [CI) and P-value of treatment effect is based on Cochran-Mantel-Haenszel (CMH) chi-squared test adjusting for country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
            <estimate_desc>Placebo group was used as the denominator for odds ratio calculation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Week 18</title>
        <description>Patients who discontinued or completed the study, or received a nonstudy intervention before having an increase in Hgb ≥ 0.5 g/dL were censored at last study visit or time of receiving nonstudy intervention, respectively.</description>
        <time_frame>Baseline to Week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Time to a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Week 18</title>
          <description>Patients who discontinued or completed the study, or received a nonstudy intervention before having an increase in Hgb ≥ 0.5 g/dL were censored at last study visit or time of receiving nonstudy intervention, respectively.</description>
          <units>Days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Q1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="14" upper_limit="43"/>
                    <measurement group_id="O2" value="14" lower_limit="8" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127" lower_limit="106" upper_limit="NA">Not available because of the insufficient number of participants with events.</measurement>
                    <measurement group_id="O2" value="43" lower_limit="22" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Week 18</title>
        <description>Patients who discontinued or completed the study, or received a nonstudy intervention before having an increase in Hgb ≥ 0.5 g/dL were censored at last study visit or time of receiving nonstudy intervention, respectively.</description>
        <time_frame>From Baseline to Week 18</time_frame>
        <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Time to a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Week 18</title>
          <description>Patients who discontinued or completed the study, or received a nonstudy intervention before having an increase in Hgb ≥ 0.5 g/dL were censored at last study visit or time of receiving nonstudy intervention, respectively.</description>
          <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
          <units>Days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Q1,1st quartile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="14" upper_limit="43"/>
                    <measurement group_id="O2" value="14" lower_limit="8" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd quartile or median</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127" lower_limit="106" upper_limit="NA">Not available because insufficient number of participants with events.</measurement>
                    <measurement group_id="O2" value="43" lower_limit="22" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3, 3rd quartile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not available because insufficient number of participants with events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="128" upper_limit="NA">Not available because insufficient number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0063</p_value>
            <p_value_desc>P-value was estimated using logrank test stratified by pooled sites.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Change in Hemoglobin With Baseline Hepcidin Level</title>
        <description>For participants who receive non-study intervention or early withdraw from the study, the time of intervention or early withdrawal will be considered as end of study, respectively.</description>
        <time_frame>Baseline to Week 18.</time_frame>
        <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Change in Hemoglobin With Baseline Hepcidin Level</title>
          <description>For participants who receive non-study intervention or early withdraw from the study, the time of intervention or early withdrawal will be considered as end of study, respectively.</description>
          <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hepcidin in 1st Tertile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="1.892"/>
                    <measurement group_id="O2" value="1.13" spread="1.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hepcidin in 3rd Tertile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="1.552"/>
                    <measurement group_id="O2" value="0.02" spread="1.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Score of the Functional Assessment of Chronic Illness Therapy Fatigue(FACIT-Fatigue) Scale Mean Change From Baseline to Week 18</title>
        <description>Summary of the actual value and change from baseline in total score of Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue Scale). Ranges from 0-52 and higher scores mean better Quality of Life (QOL). Data collected after receiving non-study intervention will not be included in the summary.</description>
        <time_frame>Baseline to Week 18</time_frame>
        <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Total Score of the Functional Assessment of Chronic Illness Therapy Fatigue(FACIT-Fatigue) Scale Mean Change From Baseline to Week 18</title>
          <description>Summary of the actual value and change from baseline in total score of Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue Scale). Ranges from 0-52 and higher scores mean better Quality of Life (QOL). Data collected after receiving non-study intervention will not be included in the summary.</description>
          <population>Only subjects who completed the study from the Modified intention to treat (mITT) population.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="9.47"/>
                    <measurement group_id="O2" value="21.5" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                    <count group_id="O2" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="6.78"/>
                    <measurement group_id="O2" value="-0.7" spread="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="7.34"/>
                    <measurement group_id="O2" value="0.2" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="7.75"/>
                    <measurement group_id="O2" value="-0.6" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="9.70"/>
                    <measurement group_id="O2" value="-0.7" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="8.35"/>
                    <measurement group_id="O2" value="0.3" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="9.82"/>
                    <measurement group_id="O2" value="-0.5" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="9.65"/>
                    <measurement group_id="O2" value="0.8" spread="9.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="8.78"/>
                    <measurement group_id="O2" value="0.0" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Injectafer</title>
          <description>2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.&#xD;
Injectafer</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline</title>
          <description>Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.&#xD;
Normal Saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood And Lymphatic System Disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections And Infestations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal And Urinary Disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, Thoracic and Mediastinal Disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="121"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="121"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="121"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="121"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="121"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary Disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="121"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="121"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, Thoracic and Mediastinal Disorders</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="121"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Disorders</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="121"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark A. Falone, MD MPH</name_or_title>
      <organization>American Regent, Inc</organization>
      <phone>631-772-3544 ext 61844</phone>
      <email>mfalone@americanregent.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

